Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2020Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
2020ASTELLAS PHARMA : Will Renew Its Corporate Website's Innovation Section
PU
2020Astellas Pharma Inc.'s Equity Buyback announced on October 31, 2019 has expir..
CI
2020Astellas Pharma Inc. Announces Consolidated Financial Results for the Nine Mo..
CI
2020Astellas Pharma Inc. and FibroGen, Inc. Announce the Submission of a Suppleme..
CI
2020ASTELLAS PHARMA : Amgen astellas biopharma to become a wholly owned amgen affili..
PU
2020ASTELLAS PHARMA : Announces Construction of New Manufacturing Facility for Activ..
AQ
2020Amgen CEO expects 25% of growth to come from Asia in next decade
RE
2020ASTELLAS PHARMA INC. : - U.S. FDA Approves Supplemental New Drug Application for..
AQ
2020Astellas Pharma Inc. Announces U.S. FDA Approves Supplemental New Drug Applic..
CI
2020ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2020Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on Oct..
CI
2019ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..
AQ
2019Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
RE
2019ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..
PU
2019Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. for approximately $670..
CI
2019Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..
RE
2019Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..
RE
2019ASTELLAS PHARMA INC. : - FDA Grants Accelerated Approval to Astellas and Seattle..
AQ
2019PFIZER INC. : - XTANDI Approved by U.S. FDA for the Treatment of Metastatic Cast..
AQ
2019U.S. FDA Approves Pfizer Inc. and Astellas Pharma Inc.'S Xtandi« (Enzalutamid..
CI
2019ASTELLAS PHARMA : Announces Key Leadership Promotions in Human Resources, Legal
AQ
2019Nikkei bounces back on trade deal hopes, steelmakers shine
RE
2019Japanese shares slip on concerns of longer trade war
RE
2019Wall Street falls as trade hopes wane
RE
2019ASTELLAS PHARMA : Presents New Data on XOSPATA in FLT3 Mutation-Positive Relapse..
AQ
2019Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merc..
AQ
2019Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy b..
RE
2019Nikkei slips on fresh global trade concerns, weak U.S. data
RE
2019ASTELLAS PHARMA : to buy U.S. biotech firm for $3 bil. to boost gene therapy
AQ
2019ASTELLAS PHARMA : ACQUISITION OF AUDENTES - Establishing a leading position in g..
PU
2019ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2019ASTELLAS PHARMA : Announces the Approval of XTANDI by the China National Medical..
AQ
2019Astellas Pharma Inc. Announces the Approval of XTANDI« (Enzalutamide) by the ..
CI
2019ASTELLAS PHARMA : and Welldoc Enter into Strategic Alliance for Digital Therapeu..
AQ
2019ASTELLAS PHARMA : and Welldoc Enter into Strategic Alliance for Digital Therapeu..
PU
2019Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics
CI
2019Astellas Pharma Inc. authorizes a Buyback Plan.
CI
2019ASTELLAS PHARMA : New England Journal of Medicine Publishes Results from Astella..
PU
2019ASTELLAS PHARMA : Announces Acquisition of Own Shares and Cancellation of Treasu..
PU
2019ASTELLAS PHARMA : Pandion and Astellas Announce Collaboration to Deliver Pancrea..
BU
2019Astellas Pharma Inc. Reports Consolidated Earnings Results for the Second Qua..
CI
2019Astellas Pharma Inc. announces an Equity Buyback for 32,000,000 shares, repre..
CI
2019Pandion and Astellas Announces Collaboration to Deliver Pancreas-Targeted Imm..
CI
2019U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP..
CI
2019ASTELLAS PHARMA : U.S. FDA Grants Fast Track Designation to Astellas for the Dev..
PU
2019Two charities to pay $6 million to resolve U.S. pharma kickback probe
RE
2019ASTELLAS PHARMA : European Commission Approves Astellas' XOSPATA™ (gilteri..
PU
2019European Commission Approves Astellas’ XOSPATA (gilteritinib) as Monotherapy ..
CI
2019ASTELLAS PHARMA : Announces Personnel Changes
PU
2019ASTELLAS PHARMA : Transfers Three Products in Asia Region to Daiichi Sankyo
PU
2019ASTELLAS PHARMA : Commits Nearly $13 Million to Fund Boston-area Start-Up Innova..
PU
2019ASTELLAS PHARMA : Seattle Genetics and Astellas Announce Results from Phase 1 Tr..
PU
2019ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2019ASTELLAS PHARMA : Receives Positive CHMP Opinion for XOSPATA« (gilteritinib) as ..
PU
2019Astellas Receives Positive CHMP Opinion for Xospata Gilteritinib as A Mono th..
CI
2019ASTELLAS PHARMA : Evrenzo« (roxadustat) Tablets Approved in Japan for the Treatm..
PU
2019Fibrogen, Inc. and Astellas Pharma Inc. Announces Approval of Roxadustat in J..
CI
2019ASTELLAS PHARMA : Seattle Genetics and Astellas Announce US FDA Grants Priority ..
PU
2019Astellas Pharma Inc. and Iota Biosciences, Inc. Enter into Collaborative Rese..
CI
2019ASTELLAS PHARMA : and iota Biosciences Enter into Collaborative Research and Dev..
PU
2019ASTELLAS PHARMA : RIKEN and Astellas Enter into Worldwide Exclusive Licensing Ag..
PU
2019Astellas Pharma Inc. agreed to acquire Worldwide license of artificial adjuva..
CI
2019Astellas Pharma Inc. and Pfizer Inc. Announce U.S. FDA Grants XTANDI« (Enzalu..
CI
2019ASTELLAS PHARMA : Yokohama City University, Tokyo University of the Arts and Ast..
PU
2019Astellas Appoints David Fryrear as New Global Head of Clinical and Research Q..
CI
2019Astellas Pharma Inc. Initiates Phase 3 Clinical Trials for Fezolinetant in Po..
CI
2019ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2019Astellas Pharma Inc. Reports Consolidated Financial Results for the First Qua..
CI
2019Astellas Announces Acceptance by the EMA of a Variation Application for Regul..
CI
2019ASTELLAS PHARMA : Announces Acceptance by the European Medicines Agency of a Var..
PU
2019Astellas Pharma Inc. and Frequency Therapeutics, Inc. Enter into License Agre..
CI
2019ASTELLAS PHARMA : and Seattle Genetics Announce Submission of Biologics License ..
PU
2019ASTELLAS PHARMA : Launch of Smyraf« Tablets - Provides a new therapeutic option ..
PU
2019ASTELLAS PHARMA : Named to FTSE4Good Index Series for the Eighth Consecutive Yea..
PU
Prev.1  2  3   4  5  6  7  8  9  10Next
Upcoming event on ASTELLAS PHARMA INC.
07/30/21